Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 586

1.

Freeze-Drying from Organic Co-Solvent Systems, Part 2: Process Modifications to Reduce Residual Solvent Levels and Improve Product Quality Attributes.

Kunz C, Schuldt-Lieb S, Gieseler H.

J Pharm Sci. 2018 Jul 12. pii: S0022-3549(18)30400-3. doi: 10.1016/j.xphs.2018.07.002. [Epub ahead of print]

PMID:
30017885
2.

Effects of Live and Heat-Inactivated E. coli Strains and Their Supernatants on Immune Regulation in HT-29 Cells.

Zimmermann C, Schild M, Kunz C, Zimmermann K, Kuntz S.

Eur J Microbiol Immunol (Bp). 2018 May 5;8(2):41-46. doi: 10.1556/1886.2018.00004. eCollection 2018 Jun 25.

3.

Avidity of α-fucose on human milk oligosaccharides and blood group-unrelated oligo/poly-fucoses is essential for potent norovirus binding targets.

Hanisch FG, Hansman GS, Morozov V, Kunz C, Schroten H.

J Biol Chem. 2018 Jun 1. pii: jbc.RA117.001369. doi: 10.1074/jbc.RA117.001369. [Epub ahead of print]

4.

No improvement in vitamin D status in German infants and adolescents between 2009 and 2014 despite public recommendations to increase vitamin D intake in 2012.

Kunz C, Hower J, Knoll A, Ritzenthaler KL, Lamberti T.

Eur J Nutr. 2018 May 18. doi: 10.1007/s00394-018-1717-y. [Epub ahead of print]

PMID:
29777304
5.

Multifunctional Hierarchical Surface Structures by Femtosecond Laser Processing.

Kunz C, Müller FA, Gräf S.

Materials (Basel). 2018 May 12;11(5). pii: E789. doi: 10.3390/ma11050789.

6.

Merits and Limitations of Dynamic Vapor Sorption Studies on the Morphology and Physicochemical State of Freeze-Dried Products.

Kunz C, Gieseler H.

J Pharm Sci. 2018 Aug;107(8):2179-2191. doi: 10.1016/j.xphs.2018.04.016. Epub 2018 Apr 24.

PMID:
29698727
7.

Factors Influencing the Retention of Organic Solvents in Products Freeze-Dried From Co-Solvent Systems.

Kunz C, Gieseler H.

J Pharm Sci. 2018 Aug;107(8):2005-2012. doi: 10.1016/j.xphs.2018.04.001. Epub 2018 Apr 9. Review.

PMID:
29649470
8.

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

Boch T, Luft T, Metzgeroth G, Mossner M, Jann JC, Nowak D, Meir F, Schumann C, Klemmer J, Brendel S, Fricke H, Kunz C, Weiß C, Hofmann WK, Nolte F.

Leuk Res. 2018 May;68:62-69. doi: 10.1016/j.leukres.2018.03.007. Epub 2018 Mar 10.

PMID:
29549809
9.

A systematic classification of death causes in multiple myeloma.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, Knaup-Gregori P, Raab MS, Schlenzka J, Bertsch U, Hillengass J, Goldschmidt H.

Blood Cancer J. 2018 Mar 8;8(3):30. doi: 10.1038/s41408-018-0068-5. No abstract available.

10.

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.

Blaes J, Thomé CM, Pfenning PN, Rübmann P, Sahm F, Wick A, Bunse T, Schmenger T, Sykora J, von Deimling A, Wiestler B, Merz C, Jugold M, Haberkorn U, Abdollahi A, Debus J, Gieffers C, Kunz C, Bendszus M, Kluge M, Platten M, Fricke H, Wick W, Lemke D.

Mol Cancer Res. 2018 May;16(5):767-776. doi: 10.1158/1541-7786.MCR-17-0563. Epub 2018 Feb 16.

PMID:
29453321
11.

Human Milk Oligosaccharides as Promising Antivirals.

Morozov V, Hansman G, Hanisch FG, Schroten H, Kunz C.

Mol Nutr Food Res. 2018 Mar;62(6):e1700679. doi: 10.1002/mnfr.201700679. Epub 2018 Mar 1. Review.

PMID:
29336526
12.

Facial asymmetry correction with moulded helmet therapy in infants with deformational skull base plagiocephaly.

Kreutz M, Fitze B, Blecher C, Marcello A, Simon R, Cremer R, Zeilhofer HF, Kunz C, Mayr J.

J Craniomaxillofac Surg. 2018 Jan;46(1):28-34. doi: 10.1016/j.jcms.2017.10.013. Epub 2017 Oct 16.

PMID:
29221913
13.

Freeze-Drying From Organic Cosolvent Systems, Part 1: Thermal Analysis of Cosolvent-Based Placebo Formulations in the Frozen State.

Kunz C, Schuldt-Lieb S, Gieseler H.

J Pharm Sci. 2018 Mar;107(3):887-896. doi: 10.1016/j.xphs.2017.11.003. Epub 2017 Nov 10.

PMID:
29133233
14.

Formation and Properties of Laser-Induced Periodic Surface Structures on Different Glasses.

Gräf S, Kunz C, Müller FA.

Materials (Basel). 2017 Aug 10;10(8). pii: E933. doi: 10.3390/ma10080933.

15.

Compositional Analysis and Metabolism of Human Milk Oligosaccharides in Infants.

Kunz C, Rudloff S.

Nestle Nutr Inst Workshop Ser. 2017;88:137-147. doi: 10.1159/000455398. Epub 2017 Mar 27. Review.

PMID:
28346931
16.

Osteo-Odonto-Keratoprosthesis in Severe Ocular Graft versus Host Disease.

Plattner K, Goldblum D, Halter J, Kunz C, Koeppl R, Gerber-Hollbach N.

Klin Monbl Augenheilkd. 2017 Apr;234(4):455-456. doi: 10.1055/s-0042-123148. Epub 2017 Mar 22. No abstract available.

PMID:
28329888
17.

Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints.

Beisel C, Benner A, Kunz C, Kopp-Schneider A.

Biom J. 2017 May;59(3):511-530. doi: 10.1002/bimj.201600047. Epub 2017 Mar 6.

PMID:
28263395
18.

In Vitro, Ex Vivo, and In Vivo Activities of Diamidines against Trypanosoma congolense and Trypanosoma vivax.

Gillingwater K, Kunz C, Braghiroli C, Boykin DW, Tidwell RR, Brun R.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02356-16. doi: 10.1128/AAC.02356-16. Print 2017 May.

19.

Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

Bochtler T, Granzow M, Stölzel F, Kunz C, Mohr B, Kartal-Kaess M, Hinderhofer K, Heilig CE, Kramer M, Thiede C, Endris V, Kirchner M, Stenzinger A, Benner A, Bornhäuser M, Ehninger G, Ho AD, Jauch A, Krämer A; Study Alliance Leukemia Investigators.

Blood. 2017 Mar 9;129(10):1333-1342. doi: 10.1182/blood-2016-09-738161. Epub 2017 Jan 24.

20.

Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations.

Kunz CU, Stallard N, Parsons N, Todd S, Friede T.

Biom J. 2017 Mar;59(2):344-357. doi: 10.1002/bimj.201500233. Epub 2016 Nov 25.

21.

Neutral oligosaccharides in feces of breastfed and formula-fed infants at different ages.

Dotz V, Adam R, Lochnit G, Schroten H, Kunz C.

Glycobiology. 2016 Dec;26(12):1308-1316. Epub 2016 Sep 9.

PMID:
27613801
22.

Influence of Gestational Age, Secretor, and Lewis Blood Group Status on the Oligosaccharide Content of Human Milk.

Kunz C, Meyer C, Collado MC, Geiger L, García-Mantrana I, Bertua-Ríos B, Martínez-Costa C, Borsch C, Rudloff S.

J Pediatr Gastroenterol Nutr. 2017 May;64(5):789-798. doi: 10.1097/MPG.0000000000001402.

PMID:
27602704
23.

First Total Synthesis, Structure Revision, and Natural History of the Smallest Cytochalasin: (+)-Periconiasin G.

Zaghouani M, Kunz C, Guédon L, Blanchard F, Nay B.

Chemistry. 2016 Oct 17;22(43):15257-15260. doi: 10.1002/chem.201603734. Epub 2016 Sep 9.

PMID:
27556729
24.

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2016 Dec;101(12):e485-e487. Epub 2016 Aug 18. No abstract available.

25.

Myeloid cells do not contribute to gender-dependent differences in disease outcome in murine cutaneous leishmaniasis.

Fischer MR, Kunz C, Dietze-Schwonberg K, Lorenz B, von Stebut E.

Cell Immunol. 2016 Oct;308:13-18. doi: 10.1016/j.cellimm.2016.07.009. Epub 2016 Jul 15.

PMID:
27444131
26.

Inhibition of Low-Grade Inflammation by Anthocyanins after Microbial Fermentation in Vitro.

Kuntz S, Kunz C, Domann E, Würdemann N, Unger F, Römpp A, Rudloff S.

Nutrients. 2016 Jul 2;8(7). pii: E411. doi: 10.3390/nu8070411.

27.

Bio-Inspired Functional Surfaces Based on Laser-Induced Periodic Surface Structures.

Müller FA, Kunz C, Gräf S.

Materials (Basel). 2016 Jun 15;9(6). pii: E476. doi: 10.3390/ma9060476. Review.

28.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.

Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, Hose D, Goldschmidt H, Granzow M, Dreger P, Ho AD, Jauch A, Schönland SO.

Blood. 2016 Jul 28;128(4):594-602. doi: 10.1182/blood-2015-10-676361. Epub 2016 Jun 2.

29.

Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.

Borghardt JM, Weber B, Staab A, Kunz C, Kloft C.

Br J Clin Pharmacol. 2016 Sep;82(3):739-53. doi: 10.1111/bcp.12999. Epub 2016 Jun 23.

30.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Baertsch MA, Schlenzka J, Mai EK, Merz M, Hillengaß J, Raab MS, Hose D, Wuchter P, Ho AD, Jauch A, Hielscher T, Kunz C, Luntz S, Klein S, Schmidt-Wolf IG, Goerner M, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Salwender H, Scheid C, Nogai A, Haenel M, Lindemann HW, Martin H, Noppeney R, Weisel K, Goldschmidt H.

BMC Cancer. 2016 Apr 25;16:290. doi: 10.1186/s12885-016-2321-2.

31.

Effects of the neurokinin-1 antagonist maropitant on canine gastric emptying assessed by radioscintigraphy and breath test.

Schmitz S, Fink T, Failing K, Borsch C, Kunz C, Clemence R, Savary-Bataille K, Neiger R.

Tierarztl Prax Ausg K Kleintiere Heimtiere. 2016 Jun 16;44(3):163-9. doi: 10.15654/TPK-150039. Epub 2016 Apr 19.

PMID:
27090486
32.

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, Lerchl T, Luckner-Minden C, Ulrich A, Koch M, Weitz J, Schneider M, Buechler MW, Zitvogel L, Herrmann T, Benner A, Kunz C, Luecke S, Springfeld C, Grabe N, Falk CS, Jaeger D.

Cancer Cell. 2016 Apr 11;29(4):587-601. doi: 10.1016/j.ccell.2016.03.005.

33.

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.

Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 18;11:585-95. doi: 10.2147/COPD.S94234. eCollection 2016.

34.

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S.

Br J Haematol. 2016 Jul;174(1):127-35. doi: 10.1111/bjh.14038. Epub 2016 Mar 15.

PMID:
26991959
35.

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis.

Raimbault A, Pierre-Eugene C, Rouquette A, Deudon C, Willems L, Chapuis N, Mathis S, Kunz C, Fricke H, Kosmider O, Bardet V, Fontenay M; Groupe Francophone des Myélodysplasies.

Oncotarget. 2016 Mar 22;7(12):14898-911. doi: 10.18632/oncotarget.7469.

36.

FUT2-dependent breast milk oligosaccharides and allergy at 2 and 5 years of age in infants with high hereditary allergy risk.

Sprenger N, Odenwald H, Kukkonen AK, Kuitunen M, Savilahti E, Kunz C.

Eur J Nutr. 2017 Apr;56(3):1293-1301. doi: 10.1007/s00394-016-1180-6. Epub 2016 Feb 24.

PMID:
26907090
37.

Femtosecond laser-induced surface structures on carbon fibers.

Sajzew R, Schröder J, Kunz C, Engel S, Müller FA, Gräf S.

Opt Lett. 2015 Dec 15;40(24):5734-7. doi: 10.1364/OL.40.005734.

PMID:
26670499
38.

Inhibition of pancreatic cancer cell migration by plasma anthocyanins isolated from healthy volunteers receiving an anthocyanin-rich berry juice.

Kuntz S, Kunz C, Rudloff S.

Eur J Nutr. 2017 Feb;56(1):203-214. doi: 10.1007/s00394-015-1070-3. Epub 2015 Oct 17.

PMID:
26476633
39.

Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach.

Borghardt JM, Weber B, Staab A, Kunz C, Formella S, Kloft C.

Br J Clin Pharmacol. 2016 Mar;81(3):538-52. doi: 10.1111/bcp.12780. Epub 2016 Feb 17.

40.

Reply to R. Warsame et al.

Bochtler T, Hegenbart U, Kunz C, Benner A, Schönland SO.

J Clin Oncol. 2015 Nov 20;33(33):3976-7. doi: 10.1200/JCO.2015.63.2141. Epub 2015 Aug 31. No abstract available.

PMID:
26324370
41.

Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.

Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 20;10:1673-83. doi: 10.2147/COPD.S86002. eCollection 2015.

42.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J.

Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29.

PMID:
26215436
43.

Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial.

Stallard N, Kunz CU, Todd S, Parsons N, Friede T.

Stat Med. 2015 Oct 15;34(23):3104-15. doi: 10.1002/sim.6567. Epub 2015 Jun 26.

44.

Two-stage phase II oncology designs using short-term endpoints for early stopping.

Kunz CU, Wason JM, Kieser M.

Stat Methods Med Res. 2017 Aug;26(4):1671-1683. doi: 10.1177/0962280215585819. Epub 2015 Jun 2.

PMID:
26037529
45.

Computer-assisted virtual planning and surgical template fabrication for frontoorbital advancement.

Soleman J, Thieringer F, Beinemann J, Kunz C, Guzman R.

Neurosurg Focus. 2015 May;38(5):E5. doi: 10.3171/2015.3.FOCUS14852.

PMID:
25929967
46.

Emergence of tick-borne encephalitis in new endemic areas in Austria: 42 years of surveillance.

Heinz FX, Stiasny K, Holzmann H, Kundi M, Sixl W, Wenk M, Kainz W, Essl A, Kunz C.

Euro Surveill. 2015 Apr 2;20(13):9-16.

47.

Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.

Haematologica. 2015 Jul;100(7):964-9. doi: 10.3324/haematol.2015.124347. Epub 2015 Apr 3.

48.

Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma.

Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, Schmitt M.

Haematologica. 2015 Jul;100(7):e285-8. doi: 10.3324/haematol.2014.116772. Epub 2015 Mar 27. No abstract available.

49.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
50.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.

Bochtler T, Hegenbart U, Kunz C, Granzow M, Benner A, Seckinger A, Kimmich C, Goldschmidt H, Ho AD, Hose D, Jauch A, Schönland SO.

J Clin Oncol. 2015 Apr 20;33(12):1371-8. doi: 10.1200/JCO.2014.57.4947. Epub 2015 Mar 16.

PMID:
25779559

Supplemental Content

Support Center